Apotex Challenge On Neurontin Generic Exclusivity May Be Too Late – Judges
This article was originally published in The Pink Sheet Daily
Executive Summary
Apotex' attempt to re-open generic exclusivity for Neurontin may be barred because the company failed to challenge FDA's patent-based approach for awarding 180-day exclusivity in earlier gabapentin litigation, appellate judges suggested Dec. 6
You may also be interested in...
Neurontin, Paxil Generic Exclusivity Disputes Dismissed By Appeals Court
The appellate judges decline to rule on the validity of FDA’s patent-by-patent approach to awarding generic marketing exclusivity in either case. Apotex’ challenge to Purepac’s gabapentin exclusivity is barred by earlier litigation, court says; FDA’s appeal stemming from paroxetine exclusivity ruling is dismissed as moot.
Neurontin, Paxil Generic Exclusivity Disputes Dismissed By Appeals Court
The appellate judges decline to rule on the validity of FDA’s patent-by-patent approach to awarding generic marketing exclusivity in either case. Apotex’ challenge to Purepac’s gabapentin exclusivity is barred by earlier litigation, court says; FDA’s appeal stemming from paroxetine exclusivity ruling is dismissed as moot.
Generic Exclusivity For Omeprazole 40 Mg Challenged By Apotex
A federal appeals court should rule on the validity of FDA’s patent-based approach to awarding exclusivity for Paxil generics because “it is an absolute certainty” that Apotex will litigate the same issue for Prilosec 40 mg, company attorney Rakoczy tells the appellate judges.